247 related articles for article (PubMed ID: 32504402)
41. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
42. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
[TBL] [Abstract][Full Text] [Related]
43. Pediatric low-grade glioma in the era of molecular diagnostics.
Ryall S; Tabori U; Hawkins C
Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789
[TBL] [Abstract][Full Text] [Related]
44. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
[TBL] [Abstract][Full Text] [Related]
45. Molecular and clinicopathologic features of gliomas harboring NTRK fusions.
Torre M; Vasudevaraja V; Serrano J; DeLorenzo M; Malinowski S; Blandin AF; Pages M; Ligon AH; Dong F; Meredith DM; Nasrallah MP; Horbinski C; Dahiya S; Ligon KL; Santi M; Ramkissoon SH; Filbin MG; Snuderl M; Alexandrescu S
Acta Neuropathol Commun; 2020 Jul; 8(1):107. PubMed ID: 32665022
[TBL] [Abstract][Full Text] [Related]
46. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
47. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
48. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
49. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
50. Under explored epigenetic modulators: role in glioma chemotherapy.
Chen YH; Zeng WJ; Wen ZP; Cheng Q; Chen XP
Eur J Pharmacol; 2018 Aug; 833():201-209. PubMed ID: 29864410
[TBL] [Abstract][Full Text] [Related]
51. Glioma epigenetics: From subclassification to novel treatment options.
Gusyatiner O; Hegi ME
Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
[TBL] [Abstract][Full Text] [Related]
52. Molecular markers and targeted therapy in pediatric low-grade glioma.
de Blank P; Fouladi M; Huse JT
J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
[TBL] [Abstract][Full Text] [Related]
53. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
54. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
Metselaar DS; Meel MH; Benedict B; Waranecki P; Koster J; Kaspers GJL; Hulleman E
EBioMedicine; 2019 Dec; 50():81-92. PubMed ID: 31735550
[TBL] [Abstract][Full Text] [Related]
55. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
56. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
57. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.
Manoharan N; Liu KX; Mueller S; Haas-Kogan DA; Bandopadhayay P
Neoplasia; 2023 Feb; 36():100857. PubMed ID: 36566593
[TBL] [Abstract][Full Text] [Related]
58. Pediatric Gliomas: Molecular Landscape and Emerging Targets.
Peeters SM; Muftuoglu Y; Na B; Daniels DJ; Wang AC
Neurosurg Clin N Am; 2021 Apr; 32(2):181-190. PubMed ID: 33781501
[TBL] [Abstract][Full Text] [Related]
59. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
Uddin MS; Mamun AA; Alghamdi BS; Tewari D; Jeandet P; Sarwar MS; Ashraf GM
Semin Cancer Biol; 2022 Aug; 83():100-120. PubMed ID: 33370605
[TBL] [Abstract][Full Text] [Related]
60. Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer.
Huffman K; Martinez ED
Front Oncol; 2013 Sep; 3():235. PubMed ID: 24058902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
